Corcept Therapeutics Inc
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
149 Commonwealth Dr, Menlo Park, Califor...Phone Number
(650) 327-3270Website
www.corcept.comRevenue
$830.8 MillionStock Symbol
CORTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
2
1
1
About Corcept Therapeutics Inc
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral scleroRead more
Corcept Therapeutics Inc Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Corcept Therapeutics Inc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Corcept Therapeutics Inc had a recent Job posting/layoffs
Corcept Therapeutics Inc, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Corcept Therapeutics Inc
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Corcept Therapeutics Inc has new funding data
Check out if Corcept Therapeutics Inc is spiking on competitors!
Check if Corcept Therapeutics Inc has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Corcept Therapeutics Inc recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Corcept Therapeutics Inc launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Corcept Therapeutics Inc
Compare insights from companies similar to Corcept Therapeutics Inc, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$680.9M
501-1,000
Private
$1.1B
2002
RD
Regina DonohueSenior Vice President, Chief Human Resources Officer
Company Profile Activity
Activity Insights
Corcept Therapeutics Inc is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Corcept Therapeutics Inc is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Corcept Therapeutics Inc.
Corcept Therapeutics Inc financials insights
Gather financial insights about Corcept Therapeutics Inc, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Stock Offering
$49M
2007
Stock Offering
$10.1M
2009
Stock Offering
$18M
2011
Stock Offering
$41.9M
Corcept Therapeutics Inc Tech Stack
A closer look at the technologies used by Corcept Therapeutics Inc
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Corcept Therapeutics Inc News & Media
Corcept Therapeutics Q2 Earnings Call Highlights
Corcept Therapeutics (NASDAQ:CORT) reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing’s syndrome franchise increased and its newly launched ovarian cancer therapy LIFYORLI contributed $47.6 million in its first quarter of availabilitySpotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1
Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season.A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound
This sale was executed under a Rule 10b5-1 trading plan adopted in March, while the stock has gained 25% over the past year.Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook
William Guyer's pre-scheduled disposition under a Rule 10b5-1 plan liquidates some direct holdings while retaining 130,000 derivative securities.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Corcept Therapeutics Inc
Sign Up For FreeTo access detailed company insights
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; an... Read More
